Vertex Pharmaceuticals Inc
Close on Nov 19, 2026Market cap $131.97BP/E 30.3Yield –
Vertex Pharmaceuticals ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) by Quarter
ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Net product revenues ($M) ($M)
Vertex Pharmaceuticals ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor): $574M in Q2 2026, up 265.8% from a year earlier. That is the highest of the 10 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Revenue Disaggregation Note & Form 8-K.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Net product revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 574 | +265.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 424 | +687.4% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 380 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 247 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 157 | – | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 53.9 | – | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-06) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-alyftrek
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?